EMErin L. Martin

Erin L. Martin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Erin L. Martin has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sex differences in cannabis use disorder study outcomes: An aggregated secondary analysis of medication trials

    by Aimee L. McRae-Clark, Erin L. Martin, Nathaniel L. Baker, Brian Neelon, Erin A. McClure, Rachel L. Tomko, Kevin M. Gray, Kathryn S. Gex

  • Open Access

    Sex differences in stress responding in a randomized, placebo-controlled clinical trial of progesterone in cannabis use disorder

    by Erin L. Martin, Nathaniel L. Baker, Brian Neelon, Michael E. Saladin, Kevin M. Gray, Zoe Watson, Aimee L. McRae-Clark

    Rationale Stress is a major contributor to relapse in individuals with cannabis use disorder (CUD). Stress responding in individuals with CUD differs by sex, suggesting a potential role for sex hormones in stress modulation and relapse prevention. The hormones progesterone and its precursor, pregnanolone, have been shown to attenuate the rewarding effects of cannabinoids, cocaine, and nicotine and curb stress-induced craving for cocaine, with evidence for greater effects in females. Objectives The present randomized controlled trial was designed to examine the impact of exogenous progesterone on stress response and cannabis use in non-treatment-seeking males and females with CUD. Methods Participants (n = 148; 82 males, 66 females) were randomized to receive twice daily progesterone 200 mg (n = 75) or placebo (n = 73) for one week while maintaining abstinence from cannabis. At end-of-treatment, participants were exposed to a laboratory stressor (Trier Social Stress Test), followed by a two-week medication-free follow-up period. Results Progesterone attenuated cannabis craving in females, but not males, and normalized relationships between subjective stress and cortisol in females and between stress and craving in both sexes. Stress-induced changes in cortisol were positively associated with time to first use during follow-up and were negatively associated with cannabis use days in the whole sample. Conclusions Results suggest a potential role for progesterone in attenuating stress-induced relapse in CUD, particularly in females.

  • Gender differences in circumstances associated with cannabis use

    by Erin L. Martin, Nathaniel L. Baker, Viswanathan Ramakrishnan, Brian Neelon, Michael E. Saladin, Aimee L. McRae‐Clark

    Background and Objectives: Identifying circumstances associated with cannabis use is critical to the development of effective interventions for cannabis use disorder (CUD) and circumstances may differ by gender. The Inventory of Drug Taking Situations (IDTS) assesses the types of situations in which individuals most often use drugs through eight subscales: dealing with (1) Unpleasant Emotions; (2) Physical Discomfort; (3) Pleasant Emotions; (4) Testing Personal Control; (5) Urges/Temptations; (6) Conflict with Others; (7) Social Pressure; and (8) Pleasant Times with Others. The aims of this study were to determine if IDTS scores varied by gender in individuals with CUD, and to ascertain if behavioral factors such as cannabis use or stress were differentially associated with IDTS scores by gender.Methods: Baseline data were obtained from a study of 148 nontreatment‐seeking individuals with CUD. Data included demographic characteristics, IDTS scores, self‐reported past 90‐day substance use, and measures of past‐month and childhood stress.Results: Women reported using cannabis more than men in negative affective contexts, namely when experiencing conflict with others, testing personal control, physical discomfort, and unpleasant emotions. IDTS subscale scores associated with negative affect and pleasant emotions were positively associated with past 90‐day cannabis use sessions across genders, use when experiencing negative affect was associated with childhood stress across genders, and use when experiencing unpleasant emotions was differentially associated with recent stress by gender.Conclusion and Scientific Significance: Findings suggest gender differences in circumstances associated with cannabis use with implications for therapeutic development for CUD.


  • Open Access

    Sex differences in normative modeling of cortical thickness in cannabis use disorder

    by Erin L. Martin, Laura M. Campbell, Kathryn Thorn, Gregory L. Sahlem, Aimee L. McRae-Clark, Andreana Benitez


  • Open Access

    Sex differences in endocannabinoid tone in a pilot study of cannabis use disorder and acute cannabis abstinence

    by Erin L. Martin, Nathaniel L. Baker, Cristina Sempio, Uwe Christians, Jost Klawitter, Aimee L. McRae‐Clark

    Cannabis use disorder (CUD) presents differently in men and women, particularly in symptoms of cannabis withdrawal. Novel pharmacotherapeutic interventions for CUD, such as those that target the endocannabinoid (eCB) system, must be developed in a manner consistent with these sex differences. The present pilot study sought to prospectively assess sex differences in cannabis withdrawal in a small sample of adults with moderate‐to‐severe CUD and to determine if withdrawal was associated with peripheral eCB and eCB congener tone. Men and women (n = 5/sex) completed 2 weeks of study participation separated by 1 month; in the latter week, participants abstained from cannabis use. Each week, participants attended in‐person laboratory visits during which blood was drawn repeatedly to assess plasma eCB and eCB congener tone. Participants also completed multiple daily ambulatory assessments to assess cannabis use and withdrawal symptoms. As anticipated, women reported a greater increase in withdrawal symptoms during the abstinent week [Δ = 9.4 (SE = 1.1); p < 0.001] than men [Δ = 1.2 (SE = 1.2); p = 0.35]. Sex differences in levels of the eCB N‐arachidonoylethanolamide (AEA), as well as the eCB congeners stearoylethanolamide (SEA) and linoleylethanolamide (LEA), were evident during abstinence at the morning time point only (p's < 0.05). LEA was associated with withdrawal symptom expression in both sexes [β = 0.16 (SE = 0.09)] and palmitoylethanolamide (PEA) [β = 0.22 (SE = 0.13)] and 2‐arachidonoylglycerol (2‐AG) [β = 0.32 (SE = 0.15)] were associated with withdrawal symptoms in women only. Pharmacotherapeutic development for CUD should consider evident sex differences in eCB and eCB congener tone during abstinence and their associations with cannabis withdrawal, as eCB‐based interventions may produce differential effects by sex.


  • Differential prevalence of Adverse Childhood Experiences (ACEs) by gender and substance used in individuals with cannabis, cocaine, opioid, and tobacco use disorders

    by Erin L. Martin, Brian Neelon, Kathleen T. Brady, Constance Guille, Nathaniel L. Baker, Viswanathan Ramakrishnan, Kevin M. Gray, Michael E. Saladin, Aimee L. McRae-Clark

    Background: Adverse childhood experiences (ACEs) show a graded association with the development of substance use disorders (SUDs) and engagement in risky substance use behaviors. Women are overrepresented among individuals with more severe childhood adversity (≥4 types of ACEs) and may be at particular risk for aberrant substance use. Objectives: To assess the prevalence of ACEs among men and women with cannabis, opioid, cocaine, and tobacco use disorders. Methods: Non-treatment-seeking individuals participating in clinical addiction research at a single site completed the ACE questionnaire and provided a detailed substance use history. Data were analyzed using proportional odds models and logistic regression. Results: Most participants (424/565; 75%) reported at least one ACE, and more than one-quarter (156/565; 27%) reported severe childhood adversity. Relative to men (n = 283), women (n = 282) reported more ACEs (OR = 1.49; p = .01) and more experiences of emotional/physical abuse (OR = 1.52; p = .02), sexual abuse (OR = 4.08; p = .04), and neglect (OR = 2.30; p < .01). Participants in the cocaine (OR = 1.87; n = .01) and opioid (OR = 2.21; p = .01) use disorder, but not cannabis use disorder (OR = 1.46; p = .08), studies reported more severe adversity relative to the tobacco group. Relative to tobacco users, emotional/physical abuse (OR = 1.92; p = .02) and neglect (OR = 2.46; p = .01) scores were higher in cocaine users and household dysfunction scores were higher in opioid users (OR = 2.67; p = .01). Conclusion: The prevalence of ACEs differs with respect to both participant gender and primary substance used. Novel SUD treatment strategies that incorporate ACEs may be uniquely beneficial in specific subpopulations of people with SUDs.


  • P48. Sex Differences in Cortical Thickness in Cannabis Use Disorder

    by Erin Martin, Kathryn Thorn, Gregory Sahlem, Aimee McRae-Clark, Andreana Benitez

  • Open Access

    A Cross-Sectional and Prospective Comparison of Medicinal Cannabis Users and Controls on Self-Reported Health

    by Nicolas J. Schlienz, Ryan Scalsky, Erin L. Martin, Heather Jackson, Joel Munson, Justin C. Strickland, Marcel O. Bonn-Miller, Mallory Loflin, Ryan Vandrey

    Introduction: Despite widespread legalization, the impact of medicinal cannabis use on patient-level health and quality of life (QOL) has not been carefully evaluated. The objective of this study was to characterize self-reported demographics, health characteristics, QOL, and health care utilization of Cannabis Users compared with Controls. Methods: A longitudinal, cross-sectional web-based survey study was completed between April 2016 and February 2018. Study participants ( n =1276) were a convenience sample of either patients with a diagnosed health condition or caregivers of a patient with a diagnosed health condition registered with the Realm of Caring Foundation (a nonprofit organization dedicated to therapeutic cannabis research and education). Participants were invited through e-mail to complete follow-up assessments every 3 months with 33% of participants completing one or more prospective follow-ups. Assessments included self-reported demographics, health care utilization, medication use, pain, anxiety, depression, sleep, and QOL. Cannabis Users ( n =808) were compared with Controls ( n =468) using negative binomial regression and linear mixed effects models testing the effect of initiation, cessation, and maintenance of medicinal cannabis use. Results: Cannabis Users self-reported significantly better QOL [ t (1054)=−4.19, p t (1045)=−4.14, p t (224)=2.90, p t (758)=3.03, p t (1150)=2.34, p t (1151)=4.38, p t (1210)=5.77, p <0.001] compared with Controls. Cannabis Users reported using fewer prescription medications (rate ratio [RR]=0.86; 95% confidence interval [CI]: 0.77–0.96) and were less likely to have a past-month emergency department visit (RR=0.61; 95% CI: 0.44–0.84) or hospital admission (RR=0.54; 95% CI: 0.34–0.87). Controls who initiated cannabis use after baseline showed significant health improvements at follow-up, and the magnitude of improvement mirrored the between-group differences observed at baseline. Conclusions: Cannabis use was associated with improved health and QOL. Longitudinal testing suggests that group differences may be due to the medicinal use of cannabis. Although bias related to preexisting beliefs regarding the health benefits of cannabis in this sample should be considered, these findings indicate that clinical trials evaluating the efficacy of defined cannabinoid products for specific health conditions are warranted.


  • Open Access

    Consideration of sex as a biological variable in the translation of pharmacotherapy for stress-associated drug seeking

    by Erin L. Martin, Elizabeth M. Doncheck, Carmela M. Reichel, Aimee L. McRae-Clark


  • Open Access

    Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an Observational Trial

    by Erin L. Martin, Justin C. Strickland, Nicolas J. Schlienz, Joel Munson, Heather Jackson, Marcel O. Bonn-Miller, Ryan Vandrey

    Background: Anxiety and depressive disorders are highly prevalent. Patients are increasingly using medicinal cannabis products to treat these disorders, but little is known about the effects of medicinal cannabis use on symptoms of anxiety and depression. The aim of the present observational study was to assess general health in medicinal cannabis users and non-using controls with anxiety and/or depression.Methods: Participants (368 Cannabis Users; 170 Controls) completed an online survey assessing anxiety and depressive symptoms, cannabis product use, sleep, quality of life, and comorbid chronic pain. Participants that completed this baseline survey were then invited to complete additional follow-up surveys at 3-month intervals. Baseline differences between Cannabis Users and Controls were assessed using independent-samples t-tests and generalized linear mixed effects models were used to assess the impact of initiating cannabis product use, sustained use, or discontinuation of use on anxiety and depressive symptoms at follow-up.Results: Medicinal cannabis use was associated with lower self-reported depression, but not anxiety, at baseline. Medicinal cannabis users also reported superior sleep, quality of life, and less pain on average. Initiation of medicinal cannabis during the follow-up period was associated with significantly decreased anxiety and depressive symptoms, an effect that was not observed in Controls that never initiated cannabis use.Conclusions: Medicinal cannabis use may reduce anxiety and depressive symptoms in clinically anxious and depressed populations. Future placebo-controlled studies are necessary to replicate these findings and to determine the route of administration, dose, and product formulation characteristics to optimize clinical outcomes.